DADC
GCVRZ

D.A. Davidson & Co’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

D.A. Davidson & Co’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-728
Closed – – 2415
2017
Q2 		$0 Sell
728
-200
-22% -$82 ﹤0.01% 2530
2017
Q1 		$0 Hold
928
– – ﹤0.01% 2633
2016
Q4 		$0 Buy
928
+28
+3% +$9 ﹤0.01% 2614
2016
Q3 		$0 Hold
900
– – ﹤0.01% 2608
2016
Q2 		$0 Hold
900
– – ﹤0.01% 2496
2016
Q1 		$0 Hold
900
– – ﹤0.01% 2460
2015
Q4 		$0 Hold
900
– – ﹤0.01% 2386
2015
Q3 		$0 Hold
900
– – ﹤0.01% 2402
2015
Q2 		$0 Hold
900
– – ﹤0.01% 2382
2015
Q1 		$0 Sell
900
-65
-7% -$45 ﹤0.01% 2273
2014
Q4 		$0 Buy
965
+200
+26% +$137 ﹤0.01% 2283
2014
Q3 		$0 Sell
765
-200
-21% -$97 ﹤0.01% 2282
2014
Q2 		$0 Hold
965
– – ﹤0.01% 2270
2014
Q1 		$0 Hold
965
– – ﹤0.01% 2318
2013
Q4 		$0 Hold
965
– – ﹤0.01% 2223
2013
Q3 		$1K Hold
965
– – ﹤0.01% 1724
2013
Q2 		$1K Buy
+965
New +$1.7K ﹤0.01% 1676

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

D.A. Davidson & Co's GCVRZ Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2017, closing a stake of 728 shares.

D.A. Davidson & Co first reported a position in GCVRZ in Q2 2013 and held it in 17 quarters. The position peaked at $1K in Q3 2013. 111 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Sanofi Contingent Value Rights position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 728 Sanofi Contingent Value Rights shares in Q3 2017.
  • D.A. Davidson & Co first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 17 quarters.
  • D.A. Davidson & Co's Sanofi Contingent Value Rights position peaked at $1K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.